18F-FDG PET/ct-positive internal mammary lymph nodes: Pathologic correlation by ultrasound-guided fine-needle aspiration and assessment of associated risk factors

American Journal of Roentgenology

Volumn 200, Issue 5, 2013, Pages 1138-1144

  Wang, Carolyn L ^a,b   Eissa, Marna J ^b,c   Rogers, James V ^a   Aravkin, Aleksandr Y ^b,d   Porter, Bruce A ^a   Beatty, J David ^a  

^a SWEDISH MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Southern Louisiana Veterans Healthcare System   (United States)

^d IBM T J WATSON RESEARCH CENTER   (United States)

Author keywords

Breast cancer; FDG PET CT; Internal mammary lymph nodes

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; PROGESTERONE RECEPTOR; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER PATIENT; CANCER SIZE; CANCER STAGING; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CYTOPATHOLOGY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PET SCANNER; PRIORITY JOURNAL; REPEAT PROCEDURE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TRIPLE NEGATIVE BREAST CANCER; TUMOR INVASION; WHOLE BODY CT; WHOLE BODY PET; BREAST TUMOR; COMPARATIVE STUDY; ENDOSCOPIC ULTRASOUND GUIDED FINE NEEDLE BIOPSY; METHODOLOGY; MIDDLE AGED; PREVALENCE; REPRODUCIBILITY; STATISTICS; UNITED STATES;

BREAST NEOPLASMS; ENDOSCOPIC ULTRASOUND-GUIDED FINE NEEDLE ASPIRATION; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PREVALENCE; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STATISTICS AS TOPIC; WASHINGTON;

MLCS; MLOWN;

EID: 84879302232     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.12.8754     Document Type: Article

References (36)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55:10-30
2. Cody HS 3rd, Urban JA. Internal mammary node status: a major prognosticator in axillary node-negative breast cancer. Ann Surg Oncol 1995; 2:32-37
3. Sugg SL, Ferguson DJ, Posner MC, Heimann R. Should internal mammary nodes be sampled in the sentinel lymph node era? Ann Surg Oncol 2000; 7:188-192
4. Veronesi U, Cascinelli N, Greco M, et al. Prognosis of breast cancer patients after mastectomy and dissection of internal mammary nodes. Ann Surg 1985; 202:702-707
5. Veronesi U, Amone P, Veronesi P, et al. The value of radiotherapy on metastatic internal mammary nodes in breast cancer: results on a large series. Ann Oncol 2008; 19:1553-1560
6. Heuts EM, van der Ent FW, von Meyenfeldt MF, Voogd AC. Internal mammary lymph drainage and sentinel node biopsy in breast cancer: a study on 1008 patients. Eur J Surg Oncol 2009; 35:252-257
7. Eubank WB, Mankoff DA, Takasugi J, et al. 18Fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer. J Clin Oncol 2001; 19:3516-3523
8. Bellon JR, Livingston RB, Eubank WB, et al. Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer (LABC). Am J Clin Oncol 2004; 27:407-410
9. Centers of Disease Control and Prevention Website. International classification of diseases, ninth revision (ICD-9). www.cdc.gov/nchs/icd/icd9. htm. Updated September 1, 2009. Accessed January 24, 2013
10. Ellis IO, Elston CW. Histologic grade. In O'Malley FP, Pinder SE, eds. Breast pathology. Philadelphia, PA: Elsevier, 2006:225-233
11. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17:1474-1481
12. Mohsin SK, Weiss H, Havighurst T, et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol 2004; 17:1545-1554
13. Wolff AC, Hammond ME, Schwartz JN, et al.; American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25:118-145
14. Parise CA, Bauer KR, Brown MM, Caggiano V. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004. Breast J 2009; 15:593-602
15. Veronesi U, Marubini E, Mariani L, Valagussa P, Zucali R. The dissection of internal mammary nodes does not improve the survival of breast cancer patients: 30-year results of a randomized trial. Eur J Cancer 1999; 35:1320-1325
16. Madsen E, Gobardhan P, Bongers V, et al. The impact on post-surgical treatment of sentinel lymph node biopsy of internal mammary lymph nodes in patients with breast cancer. Ann Surg Oncol 2007; 14:1486-1492
17. Estourgie SH, Nieweg OE, Olmos RA, Rutgers EJ, Kroon BB. Lymphatic drainage patterns from the breast. Ann Surg 2004; 239:232-237
18. Hindié E, Groheux D, Hennequin C, et al. Lymphoscintigraphy can select breast cancer patients for internal mammary chain radiotherapy. Int J Radiat Oncol Biol Phys 2012; 83:1081-1088
19. van der Ent FW, Kengen RA, van der Pol HA, Povel JA, Stroeken HJ, Hoofwijk AG. Halsted revisited: internal mammary sentinel lymph node biopsy in breast cancer. Ann Surg 2001; 234:79-84
20. Chen RC, Lin NU, Golshan M, Harris JR, Bellon Jr. Internal mammary nodes in breast cancer: diagnosis and implications for patient management-a systematic review. J Clin Oncol 2008; 26:4981-4989
21. Farrús B, Vidal-Sicart S, Velasco M, et al. Incidence of internal mammary node metastases after a sentinel lymph node technique in breast cancer and its implication in the radiotherapy plan. Int J Radiat Oncol Biol Phys 2004; 60:715-721
22. Dupont E, Cox CE, Nguyen K, et al. Utility of internal mammary lymph node removal when noted by intraoperative gamma probe detection. Ann Surg Oncol 2001; 8:833-836
23. Noushi F, Spillane AJ, Uren RF, Gebski V. Internal mammary lymph node metastasis in breast cancer: predictive models to assist with prognostic influence. Breast 2011; 20:278-283
24. Segaert I, Mottaghy F, Ceyssens S, et al. Additional value of PET-CT in staging of clinical stage IIB and III breast cancer. Breast J 2010; 16:617-624
25. Beatty JD, Precht LM, Lowe K, Atwood M. Axillary-conserving surgery is facilitated by neoadjuvant chemotherapy of breast cancer. Am J Surg 2009; 197:637-641; discussion, 641-642
26. Donegan WL. The influence of untreated internal mammary metastases upon the course of mammary cancer. Cancer 1977; 39:533-538
27. Livingston SF, Arlen M. The extended extrapleural radical mastectomy: its role in the treatment of carcinoma of the breast. Ann Surg 1974; 179:260-265
28. Veronesi U, Valagussa P. Inefficacy of internal mammary nodes dissection in breast cancer surgery. Cancer 1981; 47:170-175
29. Pugliese M, Shivaram G, Rogers J, Haseley D, Buchanan C. PET-CT imaging in the initial management of high-risk breast cancer patients: who did it help? Breast J 2009; 15:554-556
30. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, eds. AJCC cancer staging manual, 7th ed. New York, NY: Springer-Verlag, 2009:345-376
31. Heuts EM, van der Ent FW, Hulsewe KW, von Meyenfeldt MF, Voogd AC. Results of tailored treatment for breast cancer patients with internal mammary lymph node metastases. Breast 2009; 18:254-258
32. Lacour J, Bucalossi P, Cacers E, et al. Radical mastectomy versus radical mastectomy plus internal mammary dissection: five-year results of an international cooperative study. Cancer 1976; 37:206-214
33. Huang O, Wang L, Shen K, et al. Breast cancer subpopulation with high risk of internal mammary lymph nodes metastasis: analysis of 2,269 Chinese breast cancer patients treated with extended radical mastectomy. Breast Cancer Res Treat 2008; 107:379-387
34. Wang CL, MacDonald LR, Rogers JV, Aravkin A, Haseley DR, Beatty JD. Positron emission mammography: correlation of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status and 18F-FDG. AJR 2011; 197:348; [web]W247-W255
35. Aukema TS, Straver ME, Peeters MJ, et al. Detection of extra-axillary lymph node involvement with FDG PET/CT in patients with stage II-III breast cancer. Eur J Cancer 2010; 46:3205-3210
36. Champion L, Brain E, Giraudet AL, et al. Breast cancer recurrence diagnosis suspected on tumor marker rising. Cancer 2011; 117:1621-1629